Biogen value drops by $18bn after Alzheimer’s drug failure
Biogen and its partner, Eisai, confirm a decision to stop the Phase III development of aducanumab, a potential treatment for Alzheimer’s – a key part of the former’s pipeline.
Archives for March 21, 2019